Anti-Mouse PD-L1 [Clone 10F.9G2] — Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse PD-L1 [Clone 10F.9G2] — Purified in vivo PLATINUM™ Functional Grade
Product No.: P371
Clone 10F.9G2 Target PD-L1 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names Programmed Death Ligand 1, B7-H1, PD-L1, CD274 Isotype Rat IgG2b κ Applications B , FA , IHC FF , in vivo , PhenoCycler® , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen Mouse CD274 Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2831651 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 10F.9G2 recognizes an epitope on mouse PD-L1. Background PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction. Antigen Distribution PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. Ligand/Receptor PD-1 (PDCD1) NCBI Gene Bank ID UniProt.org Research Area Cancer . Costimulatory Molecules . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone 10F.9G2 is a rat monoclonal antibody that specifically targets mouse PD-L1 (programmed death ligand 1), also known as B7-H1 or CD274. This antibody is widely used in various in vivo applications involving mice, including: Common In Vivo Applications
The 10F.9G2 antibody is widely used in mouse models to target PD-L1 (CD274, B7-H1), often in combination with other antibodies or proteins that interrogate related immune checkpoint pathways or immune cell populations. The most commonly co-used antibodies and proteins in the literature are:
Most common combinations in the literature:
Additional frequently used immune-related antibodies or proteins:
In summary, the most frequently co-used antibodies or proteins with 10F.9G2 are other immune checkpoint antibodies (especially anti-PD-1, anti-CD80/B7-1, anti-PD-L1 clones such as MIH6, 10F.2H11), isotype controls, and immune cell markers relevant to the tissue/cell type being studied. Clone 10F.9G2 is a rat monoclonal antibody targeting mouse PD-L1 (CD274, B7-H1) that has generated substantial scientific findings across multiple areas of cancer immunotherapy and autoimmune disease research. This antibody has become particularly valuable due to its unique dual-blocking capability and extensive validation in preclinical models. Dual-Blocking MechanismThe defining characteristic of 10F.9G2 is its ability to simultaneously block both major PD-L1-mediated immune checkpoint pathways. Specifically, it prevents the interaction between PD-L1 and PD-1, as well as between PD-L1 and B7-1 (CD80). This dual-blocking activity distinguishes it from other anti-PD-L1 antibodies like clone 10F.2H11, which only blocks the PD-L1:B7-1 interaction while leaving PD-L1:PD-1 binding intact. The two antibodies bind to distinct, non-overlapping epitopes on PD-L1, with 10F.9G2 sharing epitope similarity with another dual blocker, MIH5. Radioimmunoconjugate ApplicationsClone 10F.9G2 has proven highly effective when radiolabeled for imaging and targeted therapy applications. When conjugated with ^89^Zr, the antibody demonstrated excellent target specificity and binding to PD-L1-overexpressing CT26/PD-L1 mouse colon cancer cells compared to weakly expressing CT26 cells. PET imaging analysis revealed 3.9-fold greater accumulation in PD-L1-overexpressing tumors. Remarkably, gemcitabine co-treatment enhanced ^89^Zr-10F.9G2 binding to 145.4% of control levels in vitro, and increased tumor uptake from 1.56% to 6.24% of the injected dose per gram in CT26 tumor-bearing mice. The F(ab')~2~ fragment of 10F.9G2, when radiolabeled with ^89^Zr, maintained target specificity in B16F10 murine melanoma cells while demonstrating earlier and higher tumor uptake than the full antibody—5.5 times greater at 2 hours post-injection in B16F10-bearing mice. Comparative Efficacy in Tumor ModelsStudies comparing 10F.9G2 with experimental PD-L1 vaccines have revealed important benchmarks for therapeutic efficacy. In BALB/c mice challenged with D2F2 and 4T1 tumor cell lines, the MVF-PD-L1(130) epitope vaccine and mAb 10F.9G2 both achieved significant tumor growth inhibition, with the vaccine showing slightly higher tumor growth inhibition (TGI) percentages in some models. However, both approaches significantly prolonged survival rates across multiple cancer models. In three different syngeneic tumor models (CT26, D2F2, and 4T1), mice treated with TT3-PD-L1(130) vaccine demonstrated higher TGI percentages compared to 10F.9G2-treated mice, though both treatments substantially outperformed PBS controls and extended survival. These findings establish 10F.9G2 as a gold-standard comparator for evaluating novel PD-L1-targeting therapeutics. Immunological EffectsThe antibody elicits robust immune responses in treated animals, including increased T cell infiltration into target tissues such as pancreatic islets in diabetes models. In tumor contexts, 10F.9G2 treatment enhances cytokine production and delays tumor growth. These effects result from relieving PD-L1-mediated immunosuppression, thereby enabling more effective antitumor and autoimmune T cell responses. Autoimmune Disease ResearchBeyond oncology, 10F.9G2 has contributed significantly to understanding immune regulation in autoimmune diseases. Research using this antibody has demonstrated that the PD-L1:B7-1 pathway restrains diabetogenic effector T cells in vivo. By comparing 10F.9G2 (dual blocker) with 10F.2H11 (B7-1-specific blocker), researchers have been able to dissect the distinct contributions of each PD-L1 interaction pathway to immune homeostasis and disease pathogenesis. The extensive citation of clone 10F.9G2 reflects its utility as a reliable tool for dissecting immune escape mechanisms, antitumor immunity, and autoimmune processes in mouse models, making it an essential reagent for preclinical immunotherapy research. Dosing regimens of clone 10F.9G2, an anti-mouse PD-L1 antibody, generally vary from 100 to 250 µg per mouse per dose, administered intraperitoneally at a frequency of 2–3 times per week across most mouse models. Key dosing details and how they may vary:
Summary Table
Regimens are highly consistent across models; dose and frequency rarely differ unless dictated by specific study design requirements or observed pharmacokinetic changes (like ADA development). In summary, clone 10F.9G2 is reliably dosed at 100–250 µg per mouse, 2–3 times weekly, intraperitoneally for most mouse models, with adjustments based on experimental context (such as strain or disease kinetics). References & Citations1. Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed 2. Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117. 3. Freeman, G. et al. (2000) J. Exp. Med. 192:1027. Technical ProtocolsCertificate of Analysis |
Related Products
Formats Available
Prod No. | Description |
|---|---|
P370 | |
P369 | |
P368 | |
P363 | |
P502 | |
P371 | |
P400 | |
P405 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
